PAVmed Inc
NASDAQ:PAVM
Intrinsic Value
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. [ Read More ]
The intrinsic value of one
PAVM
stock under the Base Case scenario is
135.86
USD.
Compared to the current market price of 1.77 USD,
PAVmed Inc
is
Undervalued by 99%.
PAVmed Inc's market capitalization is 15.2m USD.
PAVM stock price is 1.77 USD.
PAVM stock price (1.77 USD) is 99% less than its Intrinsic Value (135.86 USD).
PAVM. Open DCF Valuation
PAVM stock price (1.77 USD) is 99% less than its Relative Value (135.86 USD). Open Relative Valuation
PAVM has upside potential of 519% compared to the average analyst price target.
Open Wall St Estimates
PAVM has positive Net Debt. This means that the company has more debt (44m USD) than cash and short-term investments (22m USD).
PAVM's Revenue has grown by an exceptional 545% over the past 12 months.
PAVM's ROE (Return on Equity) has significantly increased in the last 3 years from -167% to 209%.
PAVM's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 2 754% to -784%.
PAVM has negative Operating Income for the last twelve months.
PAVM has negative Net Income for the last twelve months.
PAVM's ROE (Return on Equity) for the past 12 months is very high and is equal to 209%.
PAVM's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -784%.
PAVM has negative Gross Profit for the last twelve months.
PAVM's Revenue is forecast to grow at a rate of 247% per year over the next 3 years.
PAVM's short-term liabilties (54m USD) exceed its short-term assets (24m USD).
PAVM's long-term liabilties (87m USD) exceed its long-term assets (33m USD).
PAVM has negative Free Cash Flow for the last twelve months.
PAVM has very high three-year average ROE (Return on Equity): 240%. The company is very efficient at transforming stockholders' equity into net income.
PAVM has very high three-year average ROIC (Return on Invested Capital): 246%. The company is very efficient at using invested capital to generate operating income.
PAVM's D/E (Debt to Equity) is very low and is equal to -0.82.
PAVM's Altman Z-Score is very low and is equal to -19.27.
Fundamental Analysis
PAVmed Inc
Balance Sheet Decomposition
PAVmed Inc
| Current Assets | 24.5m |
| Cash & Short-Term Investments | 22.3m |
| Receivables | 61k |
| Other Current Assets | 2.1m |
| Non-Current Assets | 8.6m |
| PP&E | 6.1m |
| Intangibles | 1.4m |
| Other Non-Current Assets | 1.1m |
| Current Liabilities | 54.2m |
| Accounts Payable | 1.8m |
| Accrued Liabilities | 7.4m |
| Short-Term Debt | 44.2m |
| Other Current Liabilities | 777k |
| Non-Current Liabilities | 32.8m |
| Other Non-Current Liabilities | 32.8m |
Earnings Waterfall
PAVmed Inc
|
Revenue
|
2.5m
USD
|
|
Cost of Revenue
|
-6.4m
USD
|
|
Gross Profit
|
-4m
USD
|
|
Operating Expenses
|
-64.8m
USD
|
|
Operating Income
|
-68.8m
USD
|
|
Other Expenses
|
2.5m
USD
|
|
Net Income
|
-66.3m
USD
|
Free Cash Flow Analysis
PAVmed Inc
PAVM Profitability Score
Profitability Due Diligence
PAVmed Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
PAVmed Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
PAVM Solvency Score
Solvency Due Diligence
PAVmed Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
PAVmed Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PAVM Price Targets Summary
PAVmed Inc
According to Wall Street analysts, the average 1-year price target for
PAVM
is 10.97 USD
with a low forecast of 4.04 USD and a high forecast of 27.3 USD.
Ownership
PAVM Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PAVM Price
PAVmed Inc
| Average Annual Return | 3.01% |
| Standard Deviation of Annual Returns | 69.59% |
| Max Drawdown | -99% |
| Market Capitalization | 15.2m USD |
| Shares Outstanding | 9 172 330 |
| Percentage of Shares Shorted | 4.45% |
Company Profile
PAVmed Inc
Country
Industry
Market Cap
Dividend Yield
Description
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.
You don't have any saved screeners yet
